Sucupira Michel V F, Mello Francisco C A, Santos Eneida A, Niel Christian, Rolla Valeria C, Arabe Juçara, Gomes Selma A
Departamento de Virologia, Instituto Oswaldo Cruz, Av. Brasil 4365, 21040-900 Rio de Janeiro, RJ, Brazil.
Mem Inst Oswaldo Cruz. 2006 Sep;101(6):655-60. doi: 10.1590/s0074-02762006000600013.
Hepatitis B virus (HBV) molecular profiles were determined for 44 patients who were infected with human immunodeficiency virus (HIV) type 1 and had antibodies to the hepatitis B core antigen (anti-HBc), with and without other HBV serological markers. In this population, 70% of the patients were under lamivudine treatment as a component of antiretroviral therapy. HBV DNA was detected in 14 (32%) patients. Eight out of 12 (67%) HBsAg positive samples, 3/10 (30%) anti-HBc only samples, and 3/22 (14%) anti-HBs positive samples were HBV DNA positive. HBV DNA loads, measured by real time polymerase chain reaction, were much higher in the HBsAg positive patients (mean, 2.5 x 10(9) copies/ml) than in the negative ones (HBV occult infection; mean, 2.7 x 10(5) copies/ml). Nine out of the 14 HBV DNA positive patients were under lamivudine treatment. Lamivudine resistant mutations in the polymerase gene were detected in only three patients, all of them belonging to the subgroup of five HBsAg positive, HBV DNA positive patients. A low mean HBV load (2.7 x 10(5) copies/ml) and an absence of lamivudine resistant mutations were observed among the cases of HBV occult infection.
对44例感染1型人类免疫缺陷病毒（HIV）且有乙肝核心抗原抗体（抗-HBc）、伴有或不伴有其他乙肝病毒血清学标志物的患者进行了乙肝病毒（HBV）分子特征分析。在这一群体中，70%的患者接受拉米夫定治疗作为抗逆转录病毒治疗的一部分。14例（32%）患者检测到HBV DNA。12例HBsAg阳性样本中有8例（67%）、仅抗-HBc样本中有3/10例（30%）、抗-HBs阳性样本中有3/22例（14%）为HBV DNA阳性。通过实时聚合酶链反应测量的HBV DNA载量，在HBsAg阳性患者中（平均2.5×10⁹拷贝/ml）比阴性患者（HBV隐匿感染；平均2.7×10⁵拷贝/ml）高得多。14例HBV DNA阳性患者中有9例接受拉米夫定治疗。仅在3例患者中检测到聚合酶基因的拉米夫定耐药突变，所有这3例患者均属于5例HBsAg阳性、HBV DNA阳性患者的亚组。在HBV隐匿感染病例中观察到低平均HBV载量（2.7×10⁵拷贝/ml）且无拉米夫定耐药突变。
